Simplifying Global Compliance
FDAnews Drug Daily Bulletin
Abbott’s Humira Approved in Europe for Expanded Treatment of Crohn’s Disease
Aug. 31, 2012
Abbott Thursday announced that the European Commission (EC) has approved Humira (adalimumab) for the treatment of moderately active Crohn’s disease (CD) in adult patients who have had an inadequate response to conventional therapy.
Copyright ©2019. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing